Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB)
Journal of Gastroenterology and Hepatology · 2026-06 · 41 (6) · 1919-1920
DOI: 10.1111/jgh.70398 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 16.04.2026. Verfasst von Dawd S Siraj und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin, Madison, Wisconsin, USA. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- University of Wisconsin, Madison, Wisconsin, USA.
ORCID-Profile: Dawd S Siraj, Fauzia Hollnagel
Zitieren
APA
Siraj, D. S., & Hollnagel, F. (2026). Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB). Journal of Gastroenterology and Hepatology, 41(6), 1919-1920. https://doi.org/10.1111/jgh.70398
Vancouver
Siraj DS, Hollnagel F. Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB). Journal of Gastroenterology and Hepatology. 2026;41(6):1919-1920. doi:10.1111/jgh.70398
BibTeX
@article{Siraj2026,
author = {Siraj, Dawd S and Hollnagel, Fauzia},
title = {Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB)},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {6},
pages = {1919--1920},
doi = {10.1111/jgh.70398}
}
EUVIMED